Indian companies have pledged approximately $20.5 billion [1] in new foreign direct investment in the United States across several key industries.
This investment surge aims to deepen economic ties between the two nations and create thousands of American jobs. The commitments are part of a broader strategy to help India and the U.S. reach a $500 billion bilateral trade target by 2030 [2, 3].
U.S. Ambassador Sergio Gor said the pledge is the largest of its kind. The total includes a $11.75 billion [1] deal by Sun Pharmaceuticals to acquire Organon, a company based in New Jersey [1, 3]. Additionally, 12 other firms have already announced investments totaling $1.1 billion [1].
While some reports describe the pledged amount as a little over $19 billion [1], other sources cite the higher figure of $20.5 billion [2, 3]. These new commitments follow a period of steady growth in bilateral investment, with cumulative India-U.S. foreign direct investment reaching $16.4 billion [2] to date.
Ambassador Gor said Indian foreign direct investment has already supported approximately 70,800 American jobs [2]. The economic impact extends beyond employment, with $330 million [2] linked to research and development spending.
The investments are spread across the technology, manufacturing, and pharmaceutical sectors [1, 2, 3]. This diversification reflects a shift toward high-value industrial partnerships and a shared interest in strengthening supply chain resilience between the two countries.
“Indian companies have pledged approximately $20.5 billion in new foreign direct investment in the United States.”
The scale of this pledge, particularly the multi-billion dollar pharmaceutical acquisition, signals a transition from Indian firms providing services to acquiring significant U.S. industrial assets. By targeting a $500 billion trade goal, both nations are attempting to institutionalize a strategic economic partnership that reduces reliance on other global markets and accelerates technology transfers.
